Trenace

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trenace

Property Description
Active ingredient Pentoxifylline
Form Modified-release tablets, Solution for injection
Pharmacological class Hemorrheologic agent, Xanthine derivative
General purpose Supports peripheral circulation
Origin Synthetic

What Type of Medicine is Trenace (Pentoxifylline)?

Trenace is a medicinal entity whose active ingredient is Pentoxifylline, primarily categorized as a hemorrheologic agent. This compound is a synthetic xanthine derivative, meaning its chemical structure is related to methylxanthines, such as caffeine, though it is used for a different, specialized therapeutic purpose. Pentoxifylline is not a naturally derived substance; it is manufactured to specifically modify the flow characteristics of blood. The action of this agent supports the maintenance of microcirculatory integrity. This classification confirms that the medicine works by focusing uniquely on the physical properties of the blood components themselves, rather than acting as a traditional vasodilator.


Forms and General Purpose of the Hemorrheologic Agent

Trenace is primarily supplied in two pharmaceutical forms: as modified-release tablets intended for oral ingestion, and as a sterile solution for injection designated for intravenous administration. The general purpose of this medicine is to promote and enhance peripheral circulation, particularly to the extremities, by improving the capability of blood to flow through small vessels. This medicine is recognized for its role in supporting circulation and improving blood properties. This general support for peripheral blood flow is the fundamental benefit provided by the drug, utilized for its role in supporting patients experiencing reduced blood movement in their limbs.


How Trenace Works at a Basic Level (Mechanism Summary)

Trenace works by directly modifying the quality of blood flow, chiefly by increasing the flexibility of red blood cells and by reducing the overall blood viscosity (thickness). By enhancing the deformability of red blood cells, the medicine allows them to traverse narrowed or congested capillaries more efficiently. Treatments focusing on hemorrheology are associated with benefits related to blood flow enhancement in peripheral systems. This foundational action facilitates smoother, less restricted blood movement through the microvascular network, which constitutes the essential way the drug supports oxygen and nutrient transport to affected tissues.

Regulatory References

  1. Pentoxifylline - StatPearls - NCBI Bookshelf

What side effects are possible with Trenace?

Possible Side Effects and Safety Information

The safety profile of Trenace (Pentoxifylline) is derived from official regulatory documentation, which categorizes adverse reactions by the physiological systems affected and their frequency.

Adverse Reactions and System Groupings

Adverse reactions are formally grouped into System-Organ Classes (SOCs). Common adverse reactions, based on clinical trial data, typically include nausea and vomiting [FDA Label]. Other documented effects may involve the Gastrointestinal System (e.g., diarrhea, epigastric discomfort), the Nervous System (e.g., dizziness, headache), and the Skin (e.g., rash, pruritus).

System-Organ Class (Partial List) Associated Adverse Events
Gastrointestinal Disorders Nausea, Vomiting, Diarrhoea, Abdominal discomfort
Nervous System Disorders Dizziness, Headache, Tremor, Sleep disorder
Cardiac/Vascular Disorders Tachycardia, Arrhythmia, Hypotension, Flushing

Documented Serious Safety Events

The official labeling highlights the potential for serious adverse reactions. These include severe hypersensitivity reactions such as anaphylactic or anaphylactoid events, which require immediate discontinuation of the medicine. A significant concern noted in regulatory text is the risk of haemorrhage (bleeding), particularly in the retina or brain, which warrants caution, especially when used concurrently with other medications affecting coagulation [Health Canada PM].

Safety Restrictions and Special Populations

Regulatory documents establish specific restrictions on the use of this medicine. It is contraindicated in patients with a known hypersensitivity to Pentoxifylline or other xanthine derivatives, and in those with recent cerebral or retinal haemorrhage [UK SmPC]. Population-specific safety considerations apply to older adults and those with impaired renal or hepatic function, who may require closer monitoring as side effects may be more pronounced in these groups [FDA Label]. The safety and effectiveness in pediatric patients have not been established.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

The information below is strictly derived from authoritative government regulatory documents regarding acute overexposure to Trenace (Pentoxifylline).

Overdose Scope

Overdose Scope Official Regulatory Statement
Documented overdose presentations: Initial signs include flushing, fever, agitation, severe drowsiness, nausea, and vomiting.
Physiological systems affected (as stated in label): The central nervous system and cardiovascular system, potentially resulting in seizures (convulsions), hypotension (low blood pressure), and arrhythmia.
Dose-related or exposure-related factors (if applicable): Acute overexposure carries a risk of severe or life-threatening manifestations due to the substance's properties.
Emergency-response statements (as written in official documents): Seek emergency medical attention or call a Poison Control center immediately.
When immediate medical help is required (label-derived phrasing only): Immediately, as regulators mandate contact even if initial symptoms are absent, especially if loss of consciousness or seizures occur.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents): Overdose is associated with severe and potentially life-threatening effects, specifically CNS and cardiac toxicity.
Antidote information (if specified): No specific antidote is known for this substance.
Overdose-context constraints (as defined in official documents): Management is limited to symptomatic and supportive medical measures and may require intensive medical monitoring.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by listing severe central nervous system and cardiovascular manifestations that necessitate urgent professional intervention. The established management strategy is based on the official statement that no specific antidote is known, limiting treatment to symptomatic and supportive care, such as maintaining systemic blood pressure and controlling convulsions. Therefore, the required action is immediate contact with emergency services for professional medical monitoring.

Therapeutic Uses of Trenace

What Trenace Treats: Main Uses and Benefits

Symptomatic Relief of Activity-Triggered Leg Pain

Trenace (Pentoxifylline) is commonly used to help with symptoms related to physical discomfort known as intermittent claudication, a condition characterized by cramping, aching, or pain in the calves and legs that occurs during walking. The medication is applied when appropriate for this condition, which is a key symptomatic manifestation of chronic occlusive arterial disease of the limbs.

The therapeutic domains of application include managing the symptoms of intermittent claudication and is considered relevant for chronic conditions presenting with symptomatic discomfort. This therapy may assist with maintaining functional stability and helps patients cope more steadily with limitations related to activity-induced pain.

May assist with easing the discomfort that restricts functional movement.”

Quick Fact: Relief for Functional Mobility

The use of this medication is relevant for easing symptoms that interfere with daily comfort. It supports patients during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods, especially when symptoms become more noticeable during physical effort. It is applied in scenarios where additional management of discomfort is required, helping to maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Populations for Whom Use is Contraindicated

Use of Trenace (Pentoxifylline) is explicitly prohibited for patients with known hypersensitivity or intolerance to the drug, or to other methylxanthines such as caffeine or theophylline. It must not be used in patients with evidence of recent cerebral or retinal hemorrhage, acute myocardial infarction, severe cardiac arrhythmias, or a current or recent peptic ulcer, as documented in official regulatory labels.

Age and Organ Function Eligibility

The safety and effectiveness of this medication have not been established in the pediatric population (patients under 18 years of age), making this group ineligible for use. For elderly patients, use is conditional, and dose selection should be cautious, reflecting the greater frequency of decreased organ function. Eligibility is restricted for patients with severe renal impairment or severe hepatic impairment, as the drug's clearance may be altered.

Pregnancy and Lactation Status

Use during pregnancy is conditional (Pregnancy Category C) and recommended only if the potential benefit justifies the potential risk to the fetus. The drug is known to be excreted in human milk, requiring a decision to discontinue nursing or discontinue the medication, as stated in the prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Trenace (Pentoxifylline) specifies several clinically significant interaction patterns, categorized by their mechanism and outcome.

Interaction Classifications (High-Level)

Classification Interacting Agents Official Regulatory Statement
Formal Contraindication Ketorolac Co-administration is prohibited due to documented risk of increased bleeding and prolonged prothrombin time.
Pharmacodynamic Risk Anticoagulants and Platelet Inhibitors Co-administration may increase the risk of bleeding. Monitoring of prothrombin time or other hematological parameters is recommended.
Pharmacokinetic Risk Strong CYP1A2 Inhibitors (e.g., Ciprofloxacin, Cimetidine) These agents increase the exposure (plasma concentration) of pentoxifylline and its active metabolite.

Official Interaction Statements

  • Antihypertensive Agents and Antidiabetic Agents: Trenace may potentiate the effects of these drug classes, leading to increased blood pressure lowering or intensified hypoglycemic action. Periodic systemic blood pressure monitoring is recommended during co-administration with antihypertensives.
  • Theophylline: Concomitant use leads to increased Theophylline plasma levels and associated toxicity, requiring plasma level monitoring.
  • Food: Oral administration with food officially results in an increased maximum plasma concentration (Cmax) and area under the curve (AUC) for the drug and its primary metabolite.
  • Population Note: Increased systemic exposure to pentoxifylline and/or active metabolites is officially documented in patients with existing hepatic or renal impairment.

The interaction profile is structured around minimizing bleeding risk and managing the potential for increased drug exposure, both of which require specific monitoring procedures as outlined in the official prescribing information.

Mechanism of Action

Red Blood Cell Flexibility via Cyclic AMP Modulation

Pentoxifylline exerts its physiological effects through mechanisms that include the modulation of blood flow properties and the suppression of inflammatory mediator synthesis. It achieves this through molecular interactions that modulate key intracellular signaling pathways. The mechanism involves the inhibition of Phosphodiesterase (PDE) enzymes, particularly the PDE Type 4 isoform, within various cells, including erythrocytes. By inhibiting PDE, the drug increases levels of the second messenger molecule cyclic AMP ( cAMP) inside the red blood cells. This molecular change promotes red blood cell flexibility and deformability , resulting in a modification of blood viscosity and altered flow resistance in the microcirculation.

Vascular and Immunological Mechanisms

The increase in cAMP levels acts as a multi-target mechanism, influencing both vascular tone and immune cell function. In vascular smooth muscle cells, higher cAMP levels promote vasorelaxation within certain peripheral vessels. Simultaneously, in leukocytes (white blood cells), the elevated cAMP interferes with transcription factors (such as NF-kappa B), leading to the suppression of pro-inflammatory cytokine synthesis (e.g., TNF-alpha, IL-1). This action reduces leukocyte adhesion and activation, which influences local flow dynamics in the capillaries.

Dosage and Administration Information

How to Use Trenace (Pentoxifylline)

The medicine Trenace, containing Pentoxifylline, is administered primarily through two routes: oral administration using 400 mg modified-release tablets, and intravenous (IV) administration using a solution for injection. The standard usage protocol dictates that the tablets must be taken with or immediately after meals to manage potential gastrointestinal discomfort, and the tablets must be swallowed whole without being chewed or crushed due to their specific modified-release design.

Standard Regimen and Frequency

The typical adult dosing regimen begins with 400 mg administered three times daily (TID). This frequency establishes the initial exposure necessary for the drug's intended action. In cases where patients experience dose-related side effects, the regimen may be adjusted to a lower frequency of twice daily (BID), which also serves as a common maintenance schedule. The overall treatment course is generally considered a long-term therapy, with a designated minimum duration of at least eight weeks to allow for the full expression of the therapeutic effects.

Population-Specific Administration

Specific adjustments apply for patients with impaired organ function. A dose reduction is necessary for individuals with severe renal impairment (kidney function compromise) or hepatic impairment (liver function compromise) to maintain appropriate drug levels in the bloodstream. Conversely, the use of Pentoxifylline is not established or recommended for pediatric patients under the age of 18.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trenace

The following summary describes the scientific studies and research patterns related to the clinical evaluation of Trenace (Pentoxifylline), based on data from peer-reviewed scientific sources and regulatory bodies.

Evidence for Use in Symptomatic Relief of Activity-Triggered Leg Pain

Research for Trenace primarily was studied for conditions characterized by fluctuating or episodic manifestations, such as intermittent claudication, a condition characterized by painful cramping or aching in the legs that occurs during walking. This area was evaluated in trials assessing short-term or episodic symptom patterns associated with chronic occlusive arterial disease of the limbs.

Study Designs and Outcomes Measured

Studies examining this medicine were mostly Randomized Controlled Trials (RCTs). These trials often compared patients taking the medicine against a non-active comparator (placebo). The research examined measurements related to patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. Specifically, the studies monitored changes in walking capacity, measured as the Pain-Free Walking Distance (PFWD) and the Total Walking Distance (TWD).

Findings describe patterns observed in the studies related to measured walking capacity. Some trials reported measurements of walking distance that were observed in some studies to differ when compared to the placebo group. However, when multiple studies were combined in large-scale reviews, the size of the measured outcomes data show patterns related to high variability across the individual trials. Research contributes to the broader evidence landscape regarding short-term symptom patterns. Research does not determine whether an individual will respond similarly.

Long-Term Data and Follow-up Duration in Research

The evidence base largely consists of research exploring short-term symptom changes, with trial periods commonly lasting up to six months. Studies monitored responses over defined time intervals, but limited information for long-term outcomes is available. This means that the long-term changes related to outcomes related to physical discomfort, or what happens over multiple years of use, are not fully established by the existing core research.

What Remains Uncertain and Inconsistent in the Research

When researchers reviewed the entire body of evidence, one key limitation identified was the high variability (heterogeneity) of the findings. This means that the patterns observed in one study did not always align clearly with the patterns observed in another, making the overall evidence quality appear to be low to moderate. Evidence quality varies across studies, and many early trials had methodological issues that introduce uncertainty. The overall certainty related to the outcomes reflecting daily functioning or activity level remains low; research is ongoing in this area.

Frequently Asked Questions (FAQ)

Common questions about Trenace (FAQ)

Q: How quickly does Trenace start working after the first dose?

A: Studies and official information indicate that the active ingredient in Trenace, Pentoxifylline, and its main compounds reach their highest level in the bloodstream within about two to four hours after taking the modified-release tablet. However, the recommended course of treatment is a minimum of eight weeks to allow the full, intended therapeutic effects to be observed.

Q: Can Trenace be taken with over-the-counter pain medications like ibuprofen?

A: Regulatory documents state that Trenace may increase the effect of medications known as antiplatelet agents, which include some over-the-counter pain relievers. Using them together may lead to an increased risk of bleeding. Patients should always consult with a healthcare provider regarding the use of multiple medications.

Q: Is it normal to feel a little dizzy when starting Trenace?

A: Yes, official product information lists dizziness as a known adverse reaction associated with Trenace. If dizziness develops and is bothersome, a healthcare provider may suggest lowering the dose to help manage this effect.

Q: How long can someone safely stay on Trenace treatment?

A: Trenace is generally considered a long-term therapy for its approved condition, with treatment often lasting for many months or years. Official regulatory documents do not specify a maximum duration limit for continuous use, and the ongoing need for treatment is typically monitored and determined by the prescribing healthcare provider.

Q: What kind of research has been done on the long-term effects of Trenace?

A: Clinical trials primarily focused on short-term symptom changes, with most study periods lasting up to six months. Due to this, official information notes that there is limited evidence available regarding what happens over very long periods of use (multiple years).

Q: Does Trenace affect fertility in men or women?

A: Animal studies have shown effects on the fetus at high doses, leading to a recommendation that women of reproductive potential should use effective contraception during treatment. The specific effects on fertility (the ability to conceive) for men or women are not fully detailed in standard regulatory labeling.

Q: Does Trenace interact with common antidepressants?

A: Trenace may enhance the effect of antiplatelet agents, and some common antidepressants, such as SSRIs, have antiplatelet activity. This combination could potentially increase the risk of bleeding. It is important for patients to discuss all medications being taken with their healthcare provider.

Q: Can I drink alcohol while I am taking Trenace?

A: Official information does not list a direct interaction between Trenace and alcohol. However, because the medication can cause dizziness, consuming alcohol while taking it might increase the risk or severity of dizziness.

Q: What should I do if the side effects of Trenace are bothersome?

A: If you experience uncomfortable side effects, such as digestive upset or nervous system issues, regulatory guidance indicates that the dose may be reduced (often from three times a day to twice a day). If adverse effects remain bothersome, the healthcare provider typically determines if the medication should be discontinued.

Q: Does Trenace cause dry mouth or changes in taste?

A: Yes, official regulatory documents list xerostomia (dry mouth) and changes in taste as known adverse effects. These are typically classified as less common or mild reactions.

Q: Does Trenace show up on standard drug screening tests?

A: Trenace is a synthetic xanthine derivative, which means its structure is similar to compounds like caffeine. While it is not typically included in standard drug screening panels for illegal substances, it may be detectable in some specific laboratory drug screens.

Q: Are there any specific foods or drinks to avoid while using Trenace?

A: Official information states that there are no specific foods or drinks to avoid while taking Trenace. In fact, the tablets are recommended to be taken with or immediately after meals to minimize stomach upset.

Q: Can Trenace cause weight gain or weight loss?

A: Official product information reports that both weight gain and weight loss have been observed as rare or delayed adverse effects of the active ingredient in post-marketing experience.

Q: Does Trenace affect blood pressure or heart rate?

A: While controlled trials don't show it causes these effects more often than placebo, Trenace may occasionally cause small decreases in blood pressure (hypotension). Adverse reaction reports also include instances of arrhythmia (irregular heartbeat) and angina (chest pain), which warrants careful use in people with pre-existing heart conditions.

Q: Is it true that Trenace can cause insomnia or vivid dreams?

A: Official documents list insomnia (difficulty sleeping) as a known adverse effect. In rare post-marketing experiences, visual and auditory hallucinations have also been reported, though vivid dreams are not specifically listed.

Q: What are the signs of a serious allergic reaction to Trenace?

A: A serious allergic reaction, known as a hypersensitivity event, can include anaphylactic or anaphylactoid reactions and angioedema (swelling beneath the skin). These serious reactions require immediate medical attention.

Q: How long does Trenace stay in your system after stopping treatment?

A: The drug is eliminated from the body quickly. The half-life (the time it takes for half the drug to be cleared) of the active ingredient is very short, typically less than an hour, and its active compounds take only slightly longer to be cleared.

Q: Does Trenace need to be taken with food?

A: Yes, the official administration instructions state that the tablets must be taken with or immediately after meals. This requirement is in place to help reduce the potential for gastrointestinal side effects.

Q: Is there a maximum daily limit for taking Trenace?

A: The standard maximum recommended dose for adults with the approved condition is 400 mg three times a day. If a patient experiences dose-related side effects, the dosage is often adjusted downward by a healthcare provider.

Q: What are the documented benefits of Trenace that patients most often report?

A: Clinical trials documented benefits related to improved patient function. Specifically, studies reported improvements in both Pain-Free Walking Distance and Total Walking Distance for individuals experiencing pain during walking due to circulation issues.

Q: Are there specific warning signs I should look for when taking Trenace?

A: Yes, official warnings advise patients to monitor for signs of bleeding (like easy bruising or blood in the stool or urine) and signs of a severe allergic reaction (such as swelling of the face, tongue, or throat). If these signs are observed, patients are advised to seek medical attention and discontinue the medication as directed by a healthcare professional.

Q: Does the time of day I take Trenace matter?

A: While specific times (morning, noon, night) are not mandatory, official dosing instructions recommend taking the medication with meals and spacing the doses evenly throughout the day. This practice helps maintain consistent drug levels in the bloodstream.

How should Trenace be stored and disposed of?

How to Store and Dispose of Trenace (Pentoxifylline)

The official storage conditions for Trenace, as documented in regulatory labeling, are designed to maintain product quality and stability.

Storage Category Requirement
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Container Keep the product in its original container and ensure the container is tightly closed to protect it from moisture.
Child Safety The medicine must be kept out of the sight and reach of children to prevent accidental ingestion.

For disposal, unused or expired Trenace should not be flushed down the toilet. Disposal must be completed through a drug take-back program. If a take-back program is unavailable, the product may be mixed with an undesirable substance (like coffee grounds) and placed in a sealed container for household trash disposal, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trenace found in:

A-Z Index: